PT1854477T - Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas - Google Patents

Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas

Info

Publication number
PT1854477T
PT1854477T PT70051826T PT07005182T PT1854477T PT 1854477 T PT1854477 T PT 1854477T PT 70051826 T PT70051826 T PT 70051826T PT 07005182 T PT07005182 T PT 07005182T PT 1854477 T PT1854477 T PT 1854477T
Authority
PT
Portugal
Prior art keywords
treatment
plasma kallikrein
ophthalmic disorders
inhibiting plasma
peptides inhibiting
Prior art date
Application number
PT70051826T
Other languages
English (en)
Portuguese (pt)
Inventor
Belichard Pierre
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of PT1854477T publication Critical patent/PT1854477T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT70051826T 2006-03-16 2007-03-13 Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas PT1854477T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
PT1854477T true PT1854477T (pt) 2016-11-10

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
PT70051826T PT1854477T (pt) 2006-03-16 2007-03-13 Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
PT111522041T PT2374472T (pt) 2006-03-16 2007-03-13 Composições e métodos para o tratamento de afeções oftalmológicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111522041T PT2374472T (pt) 2006-03-16 2007-03-13 Composições e métodos para o tratamento de afeções oftalmológicas

Country Status (12)

Country Link
US (3) US20070270344A1 (https=)
JP (2) JP5337493B2 (https=)
AU (1) AU2007224643B2 (https=)
CA (1) CA2646285C (https=)
DK (1) DK1854477T3 (https=)
ES (2) ES2682646T3 (https=)
HU (2) HUE031701T2 (https=)
LT (2) LT2374472T (https=)
PL (1) PL1854477T3 (https=)
PT (2) PT1854477T (https=)
SI (1) SI2374472T1 (https=)
WO (1) WO2007104541A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
JP2013533206A (ja) * 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3376939B1 (en) * 2015-11-18 2022-05-11 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
EP3953395B1 (en) * 2019-04-08 2026-05-06 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
AU2004268144A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2001500A4 (en) 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2013533206A (ja) 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法

Also Published As

Publication number Publication date
LT2374472T (lt) 2018-09-25
JP2012211194A (ja) 2012-11-01
CA2646285C (en) 2020-04-28
US9107928B2 (en) 2015-08-18
ES2601554T3 (es) 2017-02-15
US20150368359A1 (en) 2015-12-24
DK1854477T3 (en) 2016-11-28
JP5337493B2 (ja) 2013-11-06
LT1854477T (lt) 2016-12-12
WO2007104541A2 (en) 2007-09-20
AU2007224643B2 (en) 2012-10-11
CA2646285A1 (en) 2007-09-20
WO2007104541A3 (en) 2008-06-26
HUE039108T2 (hu) 2018-12-28
ES2682646T3 (es) 2018-09-21
AU2007224643A1 (en) 2007-09-20
PT2374472T (pt) 2018-08-08
US20100273721A1 (en) 2010-10-28
HUE031701T2 (en) 2017-07-28
JP2009529553A (ja) 2009-08-20
US20070270344A1 (en) 2007-11-22
PL1854477T3 (pl) 2017-02-28
SI2374472T1 (sl) 2018-11-30

Similar Documents

Publication Publication Date Title
PL1854477T3 (pl) Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych
IL191283A (en) Compositions for treating eye irregularities
IL193747A0 (en) New therapeutic combinations for the treatment of depression
ZA200800464B (en) Peptides for use in the treatment of obesity
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0602178D0 (en) Therapeutic treatment
ZA200901523B (en) Use of extracts for the treatment of viral disorders
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0523961D0 (en) The treatment of ophthalmic diseases
SI1854477T1 (sl) Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
GB0610909D0 (en) Therapeutic treatment
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
GB0523964D0 (en) The treatment of ophthalmic diseases
GB0602857D0 (en) The treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment